Pharmaceutical companies Nektar Therapeutics and Bristol-Myers Squibb have expanded their collaboration to develop an anti-cancer treatment.
The treatment comprises Nektar’s bempegaldesleukin (bempeg) and Bristol-Myers' Opdivo (nivolumab). The expansion would go beyond the three pivotal studies in first-line metastatic melanoma, first-line cisplatin-ineligible metastatic urothelial cancer and first-line metastatic renal cell carcinoma (RCC) - to include additional trials in adjuvant melanoma and in muscle-invasive bladder cancer. Nektar and Bristol-Myers will also begin phase 1/2 dose escalation studies in first-line RCC.
The two companies began the partnership in 2016. The cost-sharing conditions won’t change in the expanded accord.
Bristol-Myers will also fund a Phase 1/2 dose optimization and expansion trial assessing the combo in first-line non-small cell lung cancer.
Nektar will be able to receive up to $125 million total once the first patients are dosed in the adjuvant melanoma trial ($25 million), muscle-invasive bladder cancer trial ($25 million), and NSCLC trial ($75 million).
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NKTR declined for three days, in of 317 cases, the price declined further within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NKTR entered a downward trend on June 07, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NKTR's RSI Indicator exited the oversold zone, of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for NKTR just turned positive on June 05, 2023. Looking at past instances where NKTR's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTR advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .
NKTR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.473) is normal, around the industry mean (25.287). P/E Ratio (0.000) is within average values for comparable stocks, (123.680). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.368). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (1.273) is also within normal values, averaging (313.722).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NKTR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of inhalation drug delivery systems
|MFs / NAME||Price $||Chg $||Chg %|
|MFS New Discovery Value B|
|Pioneer Intrinsic Value Y|
|Northern Multi-Mgr Glbl Listed Infra|
|Fidelity Advisor® Global Equity Inc Z|
|Columbia Global Opportunities R|
A.I.dvisor indicates that over the last year, NKTR has been loosely correlated with FULC. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTR jumps, then FULC could also see price increases.
|FULC - NKTR|
|SLS - NKTR|
|SGMO - NKTR|
|EDIT - NKTR|
|BEAM - NKTR|